FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890948368> ?p ?o ?g. }

• W2890948368 endingPage "175346661879698" @default.
• W2890948368 startingPage "175346661879698" @default.
• W2890948368 abstract "In recognition of the value of long-term real-world data, a postauthorization safety study of the inhaled corticosteroid (ICS) fluticasone propionate and long-acting β2-agonist (LABA) formoterol fumarate (fluticasone/formoterol; Flutiform®) was conducted.This was a 12-month observational study of outpatients with asthma aged ⩾ 12 years in eight European countries. Patients were prescribed fluticasone/formoterol according to the licensed indication, and independently of their subsequent enrolment in the study. They were then treated according to local standard practice. The study objectives were to evaluate the safety and effectiveness of fluticasone/formoterol under real-world conditions.The safety population for this study comprised 2539 patients (mean age 47.7 years; 94.3% aged ⩾ 18 years; 63.4% female). Most patients (1538/2539, 60.6%) had switched to fluticasone/formoterol from another ICS/LABA, primarily due to lack of efficacy (1150/2539, 45.3%). Three quarters (77.4%) of patients were treated for 12 months, and 80.6% continued fluticasone/formoterol treatment after the study. Adverse events (AEs) occurred in 60.0% patients, and 10.2% had AEs considered possibly related to fluticasone/formoterol [most commonly asthma exacerbation (2.0% patients), dysphonia (1.8%) and cough (1.1%)]. Thirty-six severe AEs, but no serious AEs, were considered possibly related to fluticasone/formoterol. The proportion of patients with controlled asthma (based on Asthma Control Test score ⩾ 20) increased from 29.4% at baseline to 67.4% at study end (last observation carried forward). The proportion of patients experiencing at least one severe exacerbation decreased from 35.8% in the year prior to enrolment to 9.8% during the study. Improvements from baseline to study end were also observed in Asthma Quality of Life scores and physician/patient reports of satisfaction with treatment.In this real-world postauthorization safety study, fluticasone/formoterol demonstrated a safety profile consistent with that seen in controlled clinical trials, with effectiveness in improving asthma control." @default.
• W2890948368 created "2018-09-27" @default.
• W2890948368 creator A5000192372 @default.
• W2890948368 creator A5003309742 @default.
• W2890948368 creator A5009277081 @default.
• W2890948368 creator A5032830080 @default.
• W2890948368 creator A5048600082 @default.
• W2890948368 creator A5057638588 @default.
• W2890948368 creator A5063608154 @default.
• W2890948368 creator A5077246003 @default.
• W2890948368 creator A5077437522 @default.
• W2890948368 creator A5089141968 @default.
• W2890948368 creator A5090072802 @default.
• W2890948368 creator A5091795166 @default.
• W2890948368 date "2018-01-01" @default.
• W2890948368 modified "2023-09-23" @default.
• W2890948368 title "Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management" @default.
• W2890948368 cites W1488753913 @default.
• W2890948368 cites W1626773437 @default.
• W2890948368 cites W1962391690 @default.
• W2890948368 cites W1963731074 @default.
• W2890948368 cites W1968405264 @default.
• W2890948368 cites W1969735103 @default.
• W2890948368 cites W1987062528 @default.
• W2890948368 cites W1989553661 @default.
• W2890948368 cites W1990444499 @default.
• W2890948368 cites W2003706075 @default.
• W2890948368 cites W2009432182 @default.
• W2890948368 cites W2024062166 @default.
• W2890948368 cites W2030768633 @default.
• W2890948368 cites W2041512941 @default.
• W2890948368 cites W2042693868 @default.
• W2890948368 cites W204439679 @default.
• W2890948368 cites W2058680631 @default.
• W2890948368 cites W2088958539 @default.
• W2890948368 cites W2098633046 @default.
• W2890948368 cites W2100197717 @default.
• W2890948368 cites W2100451358 @default.
• W2890948368 cites W2147598709 @default.
• W2890948368 cites W2153236387 @default.
• W2890948368 cites W2407210537 @default.
• W2890948368 cites W2547023985 @default.
• W2890948368 cites W2602099499 @default.
• W2890948368 cites W2745499451 @default.
• W2890948368 doi "https://doi.org/10.1177/1753466618796987" @default.
• W2890948368 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6149027" @default.
• W2890948368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30232933" @default.
• W2890948368 hasPublicationYear "2018" @default.
• W2890948368 type Work @default.
• W2890948368 sameAs 2890948368 @default.
• W2890948368 citedByCount "7" @default.
• W2890948368 countsByYear W28909483682019 @default.
• W2890948368 countsByYear W28909483682020 @default.
• W2890948368 countsByYear W28909483682023 @default.
• W2890948368 crossrefType "journal-article" @default.
• W2890948368 hasAuthorship W2890948368A5000192372 @default.
• W2890948368 hasAuthorship W2890948368A5003309742 @default.
• W2890948368 hasAuthorship W2890948368A5009277081 @default.
• W2890948368 hasAuthorship W2890948368A5032830080 @default.
• W2890948368 hasAuthorship W2890948368A5048600082 @default.
• W2890948368 hasAuthorship W2890948368A5057638588 @default.
• W2890948368 hasAuthorship W2890948368A5063608154 @default.
• W2890948368 hasAuthorship W2890948368A5077246003 @default.
• W2890948368 hasAuthorship W2890948368A5077437522 @default.
• W2890948368 hasAuthorship W2890948368A5089141968 @default.
• W2890948368 hasAuthorship W2890948368A5090072802 @default.
• W2890948368 hasAuthorship W2890948368A5091795166 @default.
• W2890948368 hasBestOaLocation W28909483681 @default.
• W2890948368 hasConcept C126322002 @default.
• W2890948368 hasConcept C197934379 @default.
• W2890948368 hasConcept C2776042228 @default.
• W2890948368 hasConcept C2776136866 @default.
• W2890948368 hasConcept C2776719499 @default.
• W2890948368 hasConcept C2777014857 @default.
• W2890948368 hasConcept C2779028295 @default.
• W2890948368 hasConcept C2779871671 @default.
• W2890948368 hasConcept C2780261241 @default.
• W2890948368 hasConcept C2781212218 @default.
• W2890948368 hasConcept C2909086917 @default.
• W2890948368 hasConcept C71924100 @default.
• W2890948368 hasConceptScore W2890948368C126322002 @default.
• W2890948368 hasConceptScore W2890948368C197934379 @default.
• W2890948368 hasConceptScore W2890948368C2776042228 @default.
• W2890948368 hasConceptScore W2890948368C2776136866 @default.
• W2890948368 hasConceptScore W2890948368C2776719499 @default.
• W2890948368 hasConceptScore W2890948368C2777014857 @default.
• W2890948368 hasConceptScore W2890948368C2779028295 @default.
• W2890948368 hasConceptScore W2890948368C2779871671 @default.
• W2890948368 hasConceptScore W2890948368C2780261241 @default.
• W2890948368 hasConceptScore W2890948368C2781212218 @default.
• W2890948368 hasConceptScore W2890948368C2909086917 @default.
• W2890948368 hasConceptScore W2890948368C71924100 @default.
• W2890948368 hasFunder F4320333641 @default.
• W2890948368 hasLocation W28909483681 @default.
• W2890948368 hasLocation W28909483682 @default.
• W2890948368 hasLocation W28909483683 @default.
• W2890948368 hasLocation W28909483684 @default.
• W2890948368 hasLocation W28909483685 @default.

• next